Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Calcified Tissue International

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00223-017-0363-3PMID 29143140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia.

  2017cited by this paper
• Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease.

  2015cited by this paper
• Hyperparathyroidism and Bone Health

  2015cited by this paper
• Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia

  2015cited by this paper
• Therapeutic management of hypophosphatemic rickets from infancy to adulthood

  2014cited by this paper
• Hypophosphatemic Rickets: Revealing Novel Control Points for Phosphate Homeostasis

  2014cited by this paper
• Bone Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR‐pQCT in Adult Patients With Hypophosphatemic Rickets

  2014cited by this paper
• Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.

  2013cited by this paper
• New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone.

  2013cited by this paper
• Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X‐linked hypophosphatemia

  2013cited by this paper
• Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets

  2012cited by this paper
• Regulation and function of the FGF23/klotho endocrine pathways.

  2012cited by this paper
• A clinician's guide to X‐linked hypophosphatemia

  2011cited by this paper
• Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling

  2011cited by this paper
• Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.

  2010cited by this paper
• ASARM mineralization hypothesis: A bridge to progress

  2010cited by this paper
• Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study.

  2010cited by this paper
• Phenotype Presentation of Hypophosphatemic Rickets in Adults

  2010cited by this paper
• Incidence and prevalence of nutritional and hereditary rickets in southern Denmark.

  2009cited by this paper
• Phosphorylation‐dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage

  2009cited by this paper
• Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.

  2008cited by this paper
• Regulation of C‐Terminal and Intact FGF‐23 by Dietary Phosphate in Men and Women

  2006cited by this paper
• Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.

  2004cited by this paper
• FGF23 is processed by proprotein convertases but not by PHEX.

  2004cited by this paper
• Hypophosphatemic osteomalacia: a report of five cases and evaluation of bone markers

  2004cited by this paper
• Prolonged high‐dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X‐linked hypophosphatemic rickets

  2003cited by this paper
• Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry

  2000cited by this paper
• Measurement of Plasma 1,25 Dihydroxyvitamin D Using a Novel Immunoextraction Technique and Immunoassay with Iodine Labelled Vitamin D Tracer

  1997cited by this paper
• A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets

  1995cited by this paper
• Guide-lines to the treatment of patients with X-linked hypophosphatemic rickets.

  1995cited by this paper
• Guide-lines to the treatment of patients with X-linked hypophosphatemic rickets.

  1995cited by this paper
• DEXA Bone Densitometry Measurements in Adults with X‐linked Hypophosphatemia

  1993cited by this paper
• Growth in children with X‐linked hypophosphataemic rickets

  1993cited by this paper
• A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.

  1992cited by this paper
• X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry.

  1991cited by this paper
• Bone mineral density of the spine and radius shaft in children with X-linked hypophosphatemic rickets (XLH).

  1991cited by this paper
• Effects of therapy in X-linked hypophosphatemic rickets.

  1991cited by this paper
• Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

  1985cited by this paper
• Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets

  1983cited by this paper
• Histomorphometric study of bone remodeling in hypophosphatemic vitamin D-resistant rickets.

  1981cited by this paper
• X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization.

  1981cited by this paper
• Stimulation of cortical bone mineralization and remodeling by phosphate and 1,25-dihydroxyvitamin D in vitamin D-resistant rickets.

  1981cited by this paper
• Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets.

  1980cited by this paper

• Experts’ consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan

  2025cites this paper
• Craniosynostosis among children with X-linked hypophosphatemia: A systematic review and meta-analysis.

  2025cites this paper
• Characterization of Novel PHEX Variants in X-linked Hypophosphatemic Rickets and Genotype-PHEX Activity Correlation

  2024cites this paper
• What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review

  2022cites this paper
• Bone Turnover Markers and Bone Mineral Density in Children with Hypophosphatemic Rickets

  2022influential citation
• Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review

  2021cites this paper
• High bone turnover and hyperparathyroidism after surgery for tumor-induced osteomalacia: A case series

  2021cites this paper
• Changes in Bone Mineral Density Following Conventional Oral Phosphonate Treatment of Hypophosphatemic Osteomalacia: A Non-Randomized Controlled Study

  2021cites this paper
• Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium

  2020cites this paper
• Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH)

  2020cites this paper
• Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review

  2020cites this paper
• Changes in Bone Mineral Density Following Conventional Oral Phosphonate Treatment of Hypophosphatemic Osteomalacia: a case-control study

  2019cites this paper
• Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.

  2019cites this paper
• Fibroblast growth factor 23 in chronic kidney disease: what is its role in cardiovascular disease?

  2019cites this paper
• The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey

  2019cites this paper
• Elevated Bone Remodeling Markers of CTX and P1NP in Addition to Sclerostin in Patients with X-linked Hypophosphatemia: A Cross-Sectional Controlled Study

  2019cites this paper
• increased bone mineral density and improved metabolic bone markers in patients with hypophosphatemic rickets osteomalacia treated with the calcimimetic cinacalcet

  2018cites this paper
• Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy

  2018cites this paper